Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3132501 | 0.98 | HCAR2 (0.43) | HCAR2CYP2C19LMNAALDH1A1TP53 | |
| SCHEMBL27356963 | 0.79 | HCAR2 (0.47) | HCAR2CYP2C19LMNAALDH1A1TP53 | |
| SCHEMBL10795202 | 0.70 | HCAR3 (0.40) | HCAR2LMNASLC6A4POLBTDP1 | |
| SCHEMBL2988124 | 0.66 | ALDH1A1 (0.43) | HCAR2LMNAALDH1A1TP53HSD11B1 | |
| Acetic Acid SCHEMBL6386413 | 0.65 | CYP2C19 (0.55) | CYP2C19LMNAALDH1A1POLBHPGD | |
| SCHEMBL6633029 | 0.65 | ALDH1A1 (0.42) | HCAR2CYP2C19LMNAALDH1A1TP53 | |
| SCHEMBL11417195 | 0.64 | FFAR3 (0.35) | — | |
| SCHEMBL2795442 | 0.64 | ALDH1A1 (0.51) | LMNAALDH1A1TP53POLBMEN1 | |
| Carbamic Acid SCHEMBL27383793 | 0.64 | POLB (0.55) | CYP2C19LMNAALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL11352535 | 0.64 | CYP2C19 (0.53) | CYP2C19LMNAALDH1A1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436013-B2 | Compounds and methods for treatment of alpha-1 antitrypsin deficiency | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-05-07 | — | — | US | claimed |
| US-20100076018-A1 | Compounds and Methods for Treatment of Alpha-1 Antitrypsin Deficiency | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-03-25 | — | — | US | claimed |
| EP-2114141-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY | University of Florida (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008143633-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY | UNIVERSITY OF FLORIDA (US) | 2008-11-27 | — | — | WO | claimed |
| US-8436013-B2 | Compounds and methods for treatment of alpha-1 antitrypsin deficiency | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436013-B2 | Compounds and methods for treatment of alpha-1 antitrypsin deficiency | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436013-B2 | Compounds and methods for treatment of alpha-1 antitrypsin deficiency | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100076018-A1 | Compounds and Methods for Treatment of Alpha-1 Antitrypsin Deficiency | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100076018-A1 | Compounds and Methods for Treatment of Alpha-1 Antitrypsin Deficiency | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| EP-2114141-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY | University of Florida (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008143633-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY | UNIVERSITY OF FLORIDA (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076018-A1 | Compounds and Methods for Treatment of Alpha-1 Antitrypsin Deficiency | SERPINA2, SERPINB1, SERPINC1 | HCAR2 3144/4885CYP2C19 2387/4885LMNA 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.